AL B. BARQAWI MD FRCS(Glasg)
Treat Only The Cancer And Preserve Quality Of Life
Home
3D Mapping Biopsy
Target Focal Therapy
Focal Laser therapy
Biography
Ongoing Clinical Trials
Botox for BPH
The Score study
Newsletter
FAQ
In the Press
Contact Me
Cryotherapy
BPH
 
 
This is the first systemic prospsective national study to collect information on the effects of salvage cryotherapy following locally recurrent prostate cancer after failed primary radiation or seed therapy

Clinicaltrials.gov

Offical Study Website
 
Salvage Cryotherapy
 
SCORE stands for Salvage Cryotherapy Registry Evaluation. Approximately 800 men who have chosen salvage cryotherapy for prostate cancer recurrence will agree to share information about themselves.

Participation in SCORE does not alter treatment nor does it affect the risks or benefits of salvage cryotherapy. Participation in SCORE is completely anonymous; name and other personal identifiers are withheld from the national registry.

The information from SCORE is collected in a national registry so that prostate cancer doctors can improve their understanding of this treatment option (salvage cryotherapy). This information will serve as the basis for future medical publications and medical lectures. In addition, the data collected as part of SCORE will help men like yourself better understand the benefits and risks of salvage cryotherapy for prostate cancer recurrence.

To speak to a patient advocate about SCORE or salvage cryotherapy call 877-722-2796
 
If you need further information about this study. Please contact Al Barqawi MD

Questions SCORE will attempt to answer:
  • Which patients will benefit from this form of cryotherapy?
  • Does the age of the patient plays a role in the success of the treatment?
  • What is the appropriate PSA level at which to initiate the salvage procedure?
  • The effect of Comorbidity (existing health problems)?
  • Can modifications of the treatment technique be beneficial?

Radiotherapy (RT)
 - An estimated 10% to 30% of men will experience BIOCHEMICAL relapse after RT, depending on patient characteristics, risk stratification, and dose (1)

- There is a continued increasing hazard rate of biochemical failure after radiotherapy beyond five years (2)
 
- Late distant metastases are more pronounced in prostate cancer patients with local failure after radiotherapy (3)

- Prostate cancer can  recur after surgery or radiotherapy in 27–53% of all patients within 10 years of initial therapy, and 16–35% of patients will receive second-line therapy” within 5 years (4)
 
1 Kupelian PA et al. Int J Radiat Oncol Biol Phys. 2005;63(5):1463-1468.
2 Rosser CJ et al. J Urol. 2003;169(6):2160-2165.
3 Coen JJ et al. J Clin Oncol. 2002;20(15):3199-3205.
4- Heidenreich A, Aus G, Bolla Met al. EAU Guidelines on Prostate Cancer. Eur Urol, 2008; 53: 68–80